You just read:

Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

News provided by

Regulus Therapeutics Inc.

Dec 19, 2017, 07:30 EST